Avelumab fails to extend PFS in ovarian cancer
January 2, 2019: Healio – A randomized phase 3 trial designed to evaluate avelumab for women with previously untreated advanced ovarian cancer failed to achieve its primary endpoint of PFS. Read more.
Avelumab fails to extend PFS in ovarian cancer
January 2, 2019: Healio – A randomized phase 3 trial designed to evaluate avelumab for women with previously untreated advanced ovarian cancer failed to achieve its primary endpoint of PFS. Read more.